- CA$70.45m
- CA$69.73m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Jul | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Helix BioPharma Corp. is a clinical-stage biopharmaceutical company developing therapies in the field of immuno-oncology for the prevention and treatment of cancer based on its proprietary technological platform DOS47. The Company’s pipeline is led by Tumor Defense Breaker L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with the Company's next-generation bi-specific antibody-drug conjugates (ADCs), in discovery. The Company is also advancing two pre-IND candidates: LEUMUNA, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and GEMCEDA, an oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.
Directors
- Slawomir Majewski CHM (65)
- Photios Michalargias CFO (58)
- Artur Gabor IND (62)
- Krzysztof Saczek IND (62)
- Adam Uszpolewicz IND (57)
- Last Annual
- July 31st, 2024
- Last Interim
- April 30th, 2025
- Incorporated
- April 30th, 2008
- Public Since
- June 3rd, 1996
- No. of Employees
- 7
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Toronto Stock Exchange- Shares in Issue
- 74,155,765
- Address
- Bay Adelaide Centre - North Tower 40, TORONTO, M5H 0B4
- Web
- https://www.helixbiopharma.com/
- Phone
- +1 6046842181
- Auditors
- CLEARHOUSE LLP
Upcoming Events for HBP
Q1 2026 Helix BioPharma Corp Earnings Release
Similar to HBP
Appili Therapeutics
Toronto Stock Exchange
Avicanna
Toronto Stock Exchange
Briacell Therapeutics
Toronto Stock Exchange
Cardiol Therapeutics
Toronto Stock Exchange
COSCIENS Biopharma
Toronto Stock Exchange
FAQ
What is the Helix Biopharma share price?
As of Today at 21:03 UTC, shares in Helix Biopharma are trading at CA$0.95. This share price information is delayed by 15 minutes.
How has the Helix Biopharma share price performed this year?
Shares in Helix Biopharma last closed at CA$0.95 and the price had moved by -19.15% over the past 365 days. In terms of relative price strength the Helix Biopharma share price has underperformed the Toronto Stock Exchange 300 Composite Index by -33.74% over the past year.
What are the analyst and broker recommendations for Helix Biopharma?
The overall consensus recommendation for Helix Biopharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Helix Biopharma dividend yield?
Helix Biopharma does not currently pay a dividend.
Does Helix Biopharma pay a dividend?
Helix Biopharma does not currently pay a dividend.
When does Helix Biopharma next pay dividends?
Helix Biopharma does not currently pay a dividend.
How do I buy Helix Biopharma shares?
To buy shares in Helix Biopharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Helix Biopharma?
As of the previous close price of CA$0.95, shares in Helix Biopharma had a market capitalisation of CA$70.45m.
Where are Helix Biopharma shares listed?
Here are the trading details for Helix Biopharma:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: HBP
What kind of share is Helix Biopharma?
Based on an overall assessment of its quality, value and momentum Helix Biopharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Helix Biopharma share price forecast for 2025?
The analyst consensus target price for shares in Helix Biopharma is CA$2.50. That is 163.16% above the last closing price of CA$0.95.
Analysts covering Helix Biopharma currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Helix Biopharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Helix Biopharma. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -9.66%.
As of the last closing price of CA$0.95, shares in Helix Biopharma were trading -5.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Helix Biopharma PE Ratio?
The Helix Biopharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Helix Biopharma?
Helix Biopharma's management team is headed by:
- Slawomir Majewski - CHM
- Photios Michalargias - CFO
- Artur Gabor - IND
- Krzysztof Saczek - IND
- Adam Uszpolewicz - IND